Login to Your Account


Evidence for link between newer HCV therapies and liver cancer mixed

By Michael Fitzhugh
Staff Writer

Friday, April 21, 2017

AMSTERDAM – Debate about whether patients taking direct-acting antiviral (DAA) therapies for hepatitis C viral (HCV) infections are at risk of developing liver cancer after achieving sustained virologic response (SVR) continued unabashed Thursday at the European Association for the Study of the Liver's (EASL) annual International Liver Congress.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription